$Rapid and sustained effect of risedronate in reducing hip fracture risk in elderly women with osteoporosis.$

Rapid and sustained effect of risedronate in reducing hip fracture risk in elderly women with osteoporosis.

Bibliográfalaš dieđut
Váldodahkkit:	Seeman, A, McClung, M, Zippel, H, Bensen, W, Cooper, C, Benhamou, C, DiGennaro, J, Zorich, N, Reginster, J
Materiálatiipa:	Journal article
Almmustuhtton:	2000

Geahča maid

Rapid and sustained hip fracture risk reduction with risedronate in elderly women with osteoporosis
Dahkki: Cooper, C, et al.
Almmustuhtton: (2001)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Dahkki: Tahir Masud, et al.
Almmustuhtton: (2009-11-01)

Once-monthly risedronate for postmenopausal osteoporosis
Dahkki: Kristina Casadei, et al.
Almmustuhtton: (2009-02-01)

Romosozumab for the treatment of osteoporosis
Dahkki: Michael R. McClung
Almmustuhtton: (2018-03-01)

Emerging Therapies for Osteoporosis
Dahkki: Michael R. McClung
Almmustuhtton: (2015-12-01)

Denosumab for the treatment of osteoporosis
Dahkki: Michael R. McClung
Almmustuhtton: (2017-03-01)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
Dahkki: Raja Bobba, et al.
Almmustuhtton: (2007-10-01)

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience.
Dahkki: Sorensen, O, et al.
Almmustuhtton: (2003)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
Dahkki: María J Moro-Álvarez, et al.
Almmustuhtton: (2008-06-01)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
Dahkki: Mizue Tanaka, et al.
Almmustuhtton: (2014-01-01)

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
Dahkki: Boyanov M, et al.
Almmustuhtton: (2012-04-01)

Risedronate as a therapeutic trial post-hysterectomy in premenopausal women to prevent osteoporosis
Dahkki: Ban Hadi Hameed
Almmustuhtton: (2018-10-01)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Dahkki: Paula Rackoff
Almmustuhtton: (2009-05-01)

Efficacy of risedronate in a post-menopausal woman affected by osteoporosis and inflammatory bowel disease
Dahkki: Stefano Palomba, et al.
Almmustuhtton: (2010-06-01)

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.
Dahkki: Delmas, P, et al.
Almmustuhtton: (2005)

The International Osteoporosis Foundation: history, objectives and achievements.
Dahkki: Cooper, C, et al.
Almmustuhtton: (2009)

The International Osteoporosis Foundation: History, objectives and achievements
Dahkki: Cooper, C, et al.
Almmustuhtton: (2009)

THE EFFECTIVENESS OF ZINC AND RISEDRONATE ON BONE TURNOVER IN RAT MODEL OF OSTEOPOROSIS ASSESSED WITH THE EXPRESSION OF β-CROSSLAPS
Dahkki: Adam Fajar, et al.
Almmustuhtton: (2019-12-01)

Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement
Dahkki: Zoya Saifi, et al.
Almmustuhtton: (2023-09-01)

Identification and treatment of osteoporosis among elderly patients with hip fractures
Dahkki: Erika Satomi, et al.
Almmustuhtton: (2009-01-01)

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate
Dahkki: Watts, N, et al.
Almmustuhtton: (2004)

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis
Dahkki: M Stevenson, et al.
Almmustuhtton: (2005-06-01)

RISEDRONATE REDUCES MICRO-STRUCTURAL DETERIORATION OF CORTICAL BONE ACCOMPANYING MENOPAUSE
Dahkki: Seeman, E, et al.
Almmustuhtton: (2010)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
Dahkki: Satoshi Soen, et al.
Almmustuhtton: (2020-12-01)

Efficacy of topical risedronate and risedronate - Eudragit E complex in a model of cutaneous leishmaniasis induced by Leishmania (Leishmania) amazonensis
Dahkki: Ma. Florencia Peralta, et al.
Almmustuhtton: (2021-05-01)

Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women.
Dahkki: Bala, Y, et al.
Almmustuhtton: (2014)

Telecarers improve osteoporosis treatment and compliance rates in secondary osteoporosis prevention for elderly hip fracture patients
Dahkki: Linsey Utami Gani, et al.
Almmustuhtton: (2023-04-01)

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Dahkki: Miller, P, et al.
Almmustuhtton: (2005)

Calcium and Strontium Coordination Polymers as Controlled Delivery Systems of the Anti-Osteoporosis Drug Risedronate and the Augmenting Effect of Solubilizers
Dahkki: Maria Vassaki, et al.
Almmustuhtton: (2021-12-01)

Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis
Dahkki: Calabria S, et al.
Almmustuhtton: (2016-04-01)

Osteoclast and Sclerostin Expression in Osteocytes in the Femoral Head with Risedronate Therapy in Patients with Hip Fractures: A Retrospective Comparative Study
Dahkki: Hwan-Hee Lee, et al.
Almmustuhtton: (2022-10-01)

Long treatment with strontium ranelate of womenwith postmenopausal osteoporosis: 10-year results
Dahkki: J Y Reginster, et al.
Almmustuhtton: (2011-04-01)

Reduced Awareness for Osteoporosis in Hip Fracture Patients Compared to Elderly Patients Undergoing Elective Hip Replacement
Dahkki: Moritz Kraus, et al.
Almmustuhtton: (2022-10-01)

Abdominal fat and hip fracture risk in the elderly: The Dubbo Osteoporosis Epidemiology Study
Dahkki: Center Jacqueline R, et al.
Almmustuhtton: (2005-02-01)

Expansion of the circadian transcriptome in Brassica rapa and genome-wide diversification of paralog expression patterns
Dahkki: Kathleen Greenham, et al.
Almmustuhtton: (2020-09-01)

Formulation and assessment of penetration potential of Risedronate chitosan nanoparticles loaded transdermal gel in the management of osteoporosis: In vitro and ex vivo screening
Dahkki: Sandhya Pathak, et al.
Almmustuhtton: (2024-06-01)

Assessment and management of osteoporosis in elderly people
Dahkki: Dennison, E, et al.
Almmustuhtton: (2000)

Changes of bone turnover markers and bone mineral density among postmenopausal Thai women with osteoporosis receiving generic risedronate
Dahkki: Ammarin Suwan, et al.
Almmustuhtton: (2024-10-01)

Impact of Risedronate on Bone Mineral Density and Quality of Life in Postmenopausal Women with Osteoporosis: The Results of 1-Year Follow up
Dahkki: Ercan Madenci, et al.
Almmustuhtton: (2003-06-01)

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
Dahkki: Vasikaran, S, et al.
Almmustuhtton: (2011)